Apr. 1 at 9:20 AM
$CMPX
Summary
--Compass Therapeutics is a clinical-stage oncology company focused on developing proprietary antibody-based therapeutics that target the intersection of angiogenesis and the immune system.
--The company is led by its flagship asset, tovecimig, which has already met its primary endpoint for Overall Response Rate (ORR) in a Phase 2/3 study for biliary tract cancer (BTC).
--The investment profile is characterized by a strong cash position (
$209M) providing runway into 2028 and high-conviction clinical readouts expected in Q2 2026.
Pipeline and Mechanism of Action
--Tovecimig (DLL4 x VEGF-A): A bispecific antibody designed to block two pathways critical to tumor vascularization. By simultaneously inhibiting DLL4 and VEGF-A, it converts productive angiogenesis into non-productive angiogenesis, triggering tumor apoptosis.
--CTX-8371 (PD-1 x PD-L1): A next-generation checkpoint inhibitor that binds to both the receptor and its ligand. Preclinical data suggests it is 100-to-1,000-fold more potent than single-target PD-1/PD-L1 inhibitors by triggering PD-1 cleavage from T-cells.
--CTX-471 (CD137 Agonist): A monoclonal antibody targeting the 4-1BB co-stimulatory receptor. It is designed to "reprogram" the tumor microenvironment without the liver toxicity seen in earlier-generation CD137 drugs.
--CTX-10726 (PD-1 x VEGF-A): A newly cleared IND candidate that combines checkpoint inhibition with anti-angiogenesis in a single tetravalent molecule.
Catalyst Readout Timeline
--April 2026: Top-line data for key secondary endpoints (Progression-Free Survival and Overall Survival) from the COMPANION-002 Phase 2/3 study of tovecimig in BTC.
--Q2 2026: Initial data presentation at a major medical meeting for CTX-8371 Phase 1 expansion cohorts in TNBC, NSCLC, and Hodgkin Lymphoma.
--Mid-2026: Initiation of a Phase 2 "basket study" for tovecimig in broader DLL4+ solid tumors (colorectal, ovarian, gastric, etc.).
--Mid-2026: Initiation of Phase 2 study for CTX-471 in NCAM+ (CD56) tumors.
--H2 2026: Initial Phase 1 clinical data expected for CTX-10726.
Competition and Competitive Positioning
--Incumbent Standard of Care: Competes against PD-1/VEGF combinations like Keytruda + Lenvima, though Compass argues its bispecific approach offers superior potency and a cleaner safety profile.
--Biliary Tract Cancer (BTC): Positioning as a second-line treatment where there is currently no established standard of care for the ~80% of patients without specific genetic mutations (HER2, FGFR2).
--Bispecific Advantage: The "StitchMabs" platform allows for a common light chain architecture, simplifying manufacturing and increasing the stability of bispecific molecules compared to traditional "mix-and-match" approaches.
Capital Structure (As of December 31, 2025)
--Fully Diluted Share Count: 202.42 million shares. Calculation: 178.32M (outstanding) + 16.35M (options) + 1.03M (RSUs) + 6.71M (pre-funded warrants).
--Fully Diluted Market Cap:
$1.05 billion (at
$5.21/share).
--Cash Position:
$209 million in cash and marketable securities expected to fund operations into 2028.
Team
--Thomas Schuetz, MD, PhD (CEO & Co-Founder): Former Venture Partner at OrbiMed with extensive oncology development experience.
--Bing Gong, PhD (CSO): Recently promoted from Head of Biologics; instrumental in the "StitchMabs" platform development.
--Cyndi Sirard, MD (CMO): Recently appointed to lead clinical strategy following the transition of lead assets into pivotal stages.
--Arjun Prasad (CCO): Recently joined as Chief Commercial Officer to prepare for potential tovecimig launch.
Bull Thesis
--De-risked Flagship: Tovecimig has already achieved statistical significance in its primary ORR endpoint; positive PFS/OS data in April could lead to BLA submission and first-mover advantage in a high-unmet-need BTC market.
--Platform Optionality: The success of CTX-8371 in early trials suggests the "StitchMabs" platform can produce highly potent, differentiated versions of established blockbuster classes.
--Strong Balance Sheet: Significant cash reserves allow the company to reach multiple major data readouts without the immediate need for dilutive financing.
Bear Thesis
--PFS/OS Uncertainty: While ORR was positive for tovecimig, the "gold standard" for regulatory approval is Overall Survival; failure to show a significant survival benefit in April would severely damage the stock.
--Crowded Immuno-Oncology Space: Compass is competing against "big pharma" (Merck, Roche, AZ) which have vastly greater resources for large-scale combination trials and commercialization.
--Binary Risk: As a clinical-stage company with no commercial revenue, the valuation is entirely dependent on clinical trial outcomes, making it highly volatile.
